v3.26.1
Fair Value Measurements - Contingent Consideration and Contingent Founder Shares (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Apr. 27, 2023
Jun. 30, 2025
Dec. 31, 2025
Dec. 31, 2024
Feb. 24, 2025
Class of Stock [Line Items]          
Common stock, par value     $ 0.0001 $ 0.0001 $ 0.0001
Threshold increase in Episodic Migraine Contingent Consideration Shares 152,998        
Number of Chronic Migraine Contingent Consideration Shares by increase in Episodic Migraine Contingent Consideration Shares 0        
Number of Contingent Consideration Shares to be issued upon Threshold Increase in Episodic Migraine Contingent Consideration Shares 0        
Reduction in number of Chronic Migraine Contingent Consideration Shares 13,996        
Minimum number of Chronic Migraine Contingent Consideration Shares after Reduction 0        
Income related to the change in fair value of contingent consideration     $ 3,499 $ 100,809  
Contingent consideration liability     $ 42 $ 3,541  
Maximum          
Class of Stock [Line Items]          
Number Of Additional Shares To Be Issued 222,653        
Reduction in Episodic Migraine Contingent Consideration Shares 13,996        
Founder Shares          
Class of Stock [Line Items]          
Number of common stock issued on conversion 95,842        
Percentage of shares unvested and subject to the restrictions and forfeiture provisions 50.00%        
Number of founder shares subject to vesting and forfeiture conditions. 47,921        
Number of founder shares forfeited   13,980      
Percentage of shares not subject to restrictions and forfeiture provisions 50.00%        
Founder Shares | Priveterra          
Class of Stock [Line Items]          
Common stock, par value $ 0.0001        
Shares Conversion Ratio 1        
Old AEON Common Stock          
Class of Stock [Line Items]          
Contingent Consideration Shares 222,653        
Migraine Phase 3 Contingent Founder Shares | Upon the achievement of the conditions for the issuance of the CD BLA Contingent Consideration Shares on or prior to the CD BLA Outside Date          
Class of Stock [Line Items]          
Number of founder shares subject to vesting and forfeiture conditions. 13,890        
Migraine Phase 3 Contingent Founder Shares | Upon the earlier of (x) the achievement of the conditions for the issuance of the Episodic Migraine Contingent Consideration Shares on or before the Episodic Migraine Outside Date and (y) the achievement of the conditions for the issuance of the Chronic Migraine Contingent Consideration Shares on or before the Chronic Migraine Outside Date          
Class of Stock [Line Items]          
Number of founder shares subject to vesting and forfeiture conditions. 20,141        
CD BLA Contingent Founder Shares          
Class of Stock [Line Items]          
Number Of Additional Shares To Be Issued 55,659        
Episodic/Chronic Migraine Contingent Founder Shares          
Class of Stock [Line Items]          
Number Of Additional Shares To Be Issued 152,998        
Number of common shares become due and payable 27,992        
Episodic/Chronic Migraine Contingent Founder Shares | Maximum          
Class of Stock [Line Items]          
Reduction in Episodic Migraine Contingent Consideration Shares 27,992        
Episodic Migraine Contingent Consideration Shares          
Class of Stock [Line Items]          
Number Of Additional Shares To Be Issued 55,659        
Chronic Migraine Contingent Consideration Shares          
Class of Stock [Line Items]          
Number Of Additional Shares To Be Issued 97,339